Cancer immunotherapy, consisting of antibodies, adoptive T-cell transfer, vaccines and cytokines, is a novel strategy for fighting cancer by artificially stimulating the immune system. It has developed rapidly in recent years, and its efficacy in hematological malignancies and solid tumors has been remarkable. It is regarded as one of the most promising methods for cancer therapy. The current trend in immunotherapy research seeks to improve its efficacy and to ensure the safety of cancer immunotherapy through the use of gene editing technologies. As it is an efficient and simple technology, the CRISPR-Cas9 system is highly anticipated to dramatically strengthen cancer immunotherapy. Intensive research on the CRISPR-Cas9 system has provided increasing confidence to clinicians that this system can be put into clinical use in the near future. This paper reviews the application and challenges of CRISPR-Cas9 in this field, based on various strategies including adaptive cell therapy and antibody therapy, and also highlights the function of CRISPR/Cas9 in the screening of new cancer targets.

中文翻译：

---

用于癌症免疫治疗的CRISPR-Cas9基因组编辑：机遇与挑战。

由抗体，过继性T细胞转移，疫苗和细胞因子组成的癌症免疫疗法是一种通过人为刺激免疫系统对抗癌症的新策略。近年来，它发展迅速，并且在血液系统恶性肿瘤和实体瘤中的疗效非常显着。它被认为是最有前途的癌症治疗方法之一。免疫疗法研究的当前趋势旨在通过使用基因编辑技术来提高其疗效并确保癌症免疫疗法的安全性。由于它是一种高效且简单的技术，因此人们高度期待CRISPR-Cas9系统能够显着增强癌症免疫疗法。对CRISPR-Cas9系统的深入研究已为临床医生提供了越来越高的信心，表明该系统可在不久的将来投入临床使用。